Dusseldorf - Delayed Quote EUR

Cue Biopharma Inc (1UC.DU)

0.6590

+0.0100

+(1.54%)

At close: April 17 at 7:30:20 PM GMT+2

Boehringer and Cue Biopharma to develop autoimmune therapies

Cue will receive a $12m upfront payment from Boehringer, along with research support.

Pharmaceutical Technology 2 days ago

CUE
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced the pricing of an underwritten public offering of (i) 13,530,780 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 3,382,695 shares of common stock and, (ii)

GlobeNewswire 3 days ago

CUE
Cue Biopharma Announces Proposed Public Offering

BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced that it is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase shares of com

GlobeNewswire 3 days ago

CUE
Cue Biopharma to Host Business Update Call and Webcast

BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced that it will host a conference call and webcast to provide a business update on Tuesday, April 15, 2025 at 4:30 p.m. ET. Conference Call and Webcast DetailsTuesday, April 15 at 4:30 p.m. ET Investors:1

GlobeNewswire 3 days ago

CUE
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need.The agreement focuses on further research and development of a novel, first-in-class bispecific compound for T cell mediated targeted depletion of specific B cells to address autoimmune and inflammatory diseases.The candidate compound has the potential to reach patients with autoimmune diseases earlier in their treatment journey and achieve long-term disease

GlobeNewswire 3 days ago

CUE
Cue Biopharma Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Cue Biopharma ( NASDAQ:CUE ) Full Year 2024 Results Key Financial Results Revenue: US$9.29m (up 69% from FY 2023). Net...

Simply Wall St. 16 days ago

CUE
Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates

Cue Biopharma (CUE) delivered earnings and revenue surprises of 18.75% and 5.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 17 days ago

CUE
Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- - Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today reported fourth quarter and full year 2024 financial results. Prioritized resources on potentially disruptive autoimmune programs while enabling maturation of clinical data from oncology programs to further su

GlobeNewswire 17 days ago

CUE
Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength?

TG Therapeutics (TGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks last month

TGTX

CUE
Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced the grant of an inducement option award to its newly appointed interim chief development officer, Daniel Baker, M.D. The grant was approved by a majority of the independent directors of the Compa

GlobeNewswire 4 months ago

CUE
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, announced today that it will take part in an unplugged fireside discussion at the Piper Sandler 36th Annual Healthcare Conference being held in New York, NY, Dec 3-5, 2024. During the fireside discussion, Cue Biopharma

GlobeNewswire 4 months ago

CUE
Cue Biopharma Third Quarter 2024 Earnings: Beats Expectations

Cue Biopharma ( NASDAQ:CUE ) Third Quarter 2024 Results Key Financial Results Revenue: US$3.34m (up 59% from 3Q 2023...

Simply Wall St. 4 months ago

CUE
Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Tops Revenue Estimates

Cue Biopharma (CUE) delivered earnings and revenue surprises of 15% and 205.22%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 4 months ago

CUE
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today provided a business and financial update for the third quarter of 2024. Recent Business Highlights Presented positive updated data from the Phase 1 trials of CUE-101 and CUE-102 at the Society for Immunotherapy o

GlobeNewswire 4 months ago

CUE
Cue Biopharma Announces Strategic Organizational Transition

Daniel Baker, M.D., will join Cue Biopharma’s executive team as interim chief development officer (CDO), effective Monday, November 25, 2024Anish Suri, Ph.D., president & chief scientific officer (CSO) of Cue Biopharma, to transition to principal research and immunology advisor BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific

GlobeNewswire 5 months ago

CUE
Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, announced today that it will take part in a fireside chat at the Stifel 2024 Healthcare Conference being held in New York, NY, November 18-19, 2024. During the fireside chat, Cue Biopharma will highlight current update

GlobeNewswire 5 months ago

CUE
Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

Objective response rate (ORR) of 46%, 12-month overall survival (OS) of 91.3% and a median overall survival (mOS) of 21.8 months in first line (1L) HPV+ R/M HNSCC patients treated with CUE-101 and KEYTRUDA® (pembrolizumab)ORR of 50% in 1L patients treated with CUE-101 and pembrolizumab with low PD-L1 expression (combined positive score (CPS) 1-19) 67% overall disease control rate (DCR) in late-stage pancreatic cancer patients treated with CUE-102 monotherapy, including an unconfirmed partial res

GlobeNewswire 5 months ago

CUE
Cue Biopharma (NASDAQ:CUE) adds US$31m to market cap in the past 7 days, though investors from three years ago are still down 89%

This month, we saw the Cue Biopharma, Inc. ( NASDAQ:CUE ) up an impressive 135%. But that is meagre solace in the face...

Simply Wall St. 6 months ago

CUE
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced it will deliver an oral and a poster presentation on the company’s Immuno-STAT™ clinical assets CUE-101 and CUE-102, representative of the CUE-100 series, at the Society for Immunotherapy of Cancer’s 39th Annual Meeting (SITC 2024). The conference will

GlobeNewswire 6 months ago

CUE
Cue Biopharma Announces Pricing of $12.0 Million Public Offering

BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced the pricing of an underwritten public offering of (i) 11,564,401 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 2,891,100 shares of common stock and, (ii) to certain investors in lieu of common stock, pre-

GlobeNewswire 6 months ago

CUE

Performance Overview

Return	1UC.DU	S&P 500 (^GSPC)
YTD	-29.89%	-10.18%
1-Year	-55.17%	+5.19%
3-Year	-61.46%	+20.26%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Cue Biopharma Inc (1UC.DU)

Boehringer and Cue Biopharma to develop autoimmune therapies

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

Cue Biopharma Announces Proposed Public Offering

Cue Biopharma to Host Business Update Call and Webcast

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Cue Biopharma Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates

Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength?

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

Cue Biopharma Third Quarter 2024 Earnings: Beats Expectations

Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Tops Revenue Estimates

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Cue Biopharma Announces Strategic Organizational Transition

Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

Cue Biopharma (NASDAQ:CUE) adds US$31m to market cap in the past 7 days, though investors from three years ago are still down 89%

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

Performance Overview